HIGHLIGHTS
- What: The participants enrolled in the study were from two of the all-vaccine group showed a uniform distribution.
- Who: Kusnandi Rusmil and colleagues from the Department of Child Health, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin Hospital have published the research work: Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac®) as a Booster Dose against COVID-19 in Indonesian Adults, in the Journal: Vaccines 2024, 540 of 31/Oct/2022
- How: The results showed that compared with the control the investigational product had inferior effectiveness 14 days after . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.